ampicillin has been researched along with rifaximin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Finegold, SM; Molitoris, D; Väisänen, ML | 1 |
| Biedenbach, DJ; Fritsche, TR; Jones, RN | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for ampicillin and rifaximin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for ampicillin and rifaximin
| Article | Year |
|---|---|
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
Topics: Ampicillin; Bacteria, Anaerobic; Feces; Microbial Sensitivity Tests; Neomycin; Nitro Compounds; Rifamycins; Rifaximin; Sulbactam; Teicoplanin; Thiazoles; Vancomycin | 2009 |
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
Topics: Anti-Bacterial Agents; Diarrhea; Dioxolanes; Fluoroquinolones; Gastroenteritis; Gram-Negative Bacteria; Humans; Piperazines; Population Surveillance; Prodrugs | 2009 |